HTG Molecular Diagnostics, Inc. (HTGM) PT Set at $6.00 by HC Wainwright
HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) in a report released on Friday morning. The firm currently has a buy rating on the medical research company’s stock.
A number of other research analysts have also recently commented on HTGM. ValuEngine raised HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Monday, July 17th. Zacks Investment Research raised HTG Molecular Diagnostics from a sell rating to a hold rating in a research report on Tuesday, July 18th. Canaccord Genuity upped their price target on HTG Molecular Diagnostics from $5.50 to $6.50 and gave the company a hold rating in a research report on Wednesday, April 19th. Finally, Rodman & Renshaw upped their price target on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the company a buy rating in a research report on Tuesday, May 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $5.75.
HTG Molecular Diagnostics (HTGM) opened at 2.3335 on Friday. The company’s market cap is $22.23 million. The firm’s 50-day moving average price is $2.61 and its 200 day moving average price is $3.37. HTG Molecular Diagnostics has a 52-week low of $1.20 and a 52-week high of $13.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings results on Monday, May 15th. The medical research company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.15. HTG Molecular Diagnostics had a negative net margin of 440.31% and a negative return on equity of 1,538.49%. The firm had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $2.44 million. On average, equities analysts predict that HTG Molecular Diagnostics will post ($2.25) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) PT Set at $6.00 by HC Wainwright” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-pt-set-at-6-00-by-hc-wainwright/1465444.html.
A number of hedge funds have recently modified their holdings of HTGM. Granahan Investment Management Inc. MA bought a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $228,000. Two Sigma Securities LLC bought a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $150,000. UBS Group AG bought a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $137,000. Finally, Renaissance Technologies LLC boosted its stake in shares of HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares during the period. 28.04% of the stock is currently owned by institutional investors and hedge funds.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.